

Glutathione S-Transferase enzyme (GSTT1 and GSTM1) Gene Polymorphisms and Oxidative Stress in Egyptian Patients with End Stage Renal Disease

Afaf EL-Said¹, A. F. Abde-Aziz² and Basma AL-Sayed Ebead^{2*}

¹Genetics Unit, Faculty of Medicine, Mansoura University, Mansoura, Egypt.

²Division of Biochemistry, Chemistry Department, Faculty of Science, Mansoura University, Mansoura, Egypt.

ABSTRACT

Glutathione S-transferase enzyme (*GSTT1* and *GSTM1*) gene polymorphisms have been associated with the genetic susceptibility to end stage renal disease (ESRD) in different populations. We investigated the association between *GSTT1* and *GSTM1* genes, and ESRD in Egyptian population. The samples of 133 ESRD and 91 control subjects were collected, and their clinical characteristics were assayed. Glutathione S-transferase enzyme (*GSTT1* and *GSTM1*) gene polymorphisms were detected by polymerase chain reaction (PCR). Serum level of malondialdehyde (MDA), the oxidative stress and lipid peroxidation biomarker, and plasma glutathione S-transferase enzyme (GST), the antioxidant enzyme, were estimated in the ESRD patients as well as in the control subjects. We demonstrated the association of MDA and GST enzyme levels with *GSTT1* and *GSTM1* genotypes. We investigated the association between MDA and lipid parameters in the ESRD patients. Increased of the *GSTM1* deletion genotype, (*GSTT1/0*) and both deletion genotypes (0/0) in the ESRD patients when compared with the control subjects ($P < 0.0001$, OR = 3.786, 95% CI = 2.151-6.664), ($P = 0.001$, OR = 3.172, 95% CI = 1.595-6.308) and ($P = 0.045$, OR = 1.945, 95% CI = 1.009-3.749), respectively. Highly significant increase of MDA level in the ESRD patients as compared with the control subjects ($P < 0.0001$). Highly significant decrease of GST enzyme level in the ESRD patients as compared with the control subjects ($P < 0.0001$). The level of MDA is significantly increased in all GST genotypes in the ESRD patients as compared with the control group. Also, there were significant association between The genetic risk factors of *GSTT1* and *GSTM1* genes in the ESRD, and high level of MDA in the ESRD patients, while the level of GST enzyme is significantly decreased in GST genotypes except the both deletion (0/0) genotypes, in which the level of GST enzyme is not significantly decreased in the ESRD patients as compared with the control subjects. There are significant association between the genetic risk factors of *GSTT1* and *GSTM1* genes in the ESRD, (*GSTM1* null and *GSTT1/0* genotypes), and low level of GST enzyme in the ESRD patients. There were significant positive correlation between MDA and total cholesterol, triglyceride, and LDL-cholesterol, and significant negative correlation between MDA and HDL-cholesterol in the ESRD patients as compared with the control subjects. In conclusion, the *GSTM1* (null) genotype, (*GSTT1/0*) and (0/0) genotypes are independent risk factors for ESRD. The oxidative stress and lipid abnormalities are associated with ESRD in the studied Egyptian population.

*Corresponding author: Email: Ba_Janna2002@yahoo.com.

Keywords: Glutathione S-transferase enzyme (GSTT1 and GSTM1) gene polymorphisms, End stage renal disease, Malondialdehyde, Glutathione S-transferase enzyme, Oxidative stress.

1. INTRODUCTION

Over 1.1 million patients are estimated to have end stage renal disease (ESRD) world-wide, and an addition of 7% annually. In USA incidence and prevalence counts are expected to increase by 44 and 85%, respectively, from 2000 to 2015 and incidence and prevalence rates per million population by 32 and 70%. In the developing countries growth of ESRD population has similar trends. Average incidence of ESRD in Middle East countries with similar renal care systems is 93 per million population (Malekmakan et al., 2009). ESRD represents a clinical condition in which there has been an irreversible loss of endogenous renal function. Patients with ESRD must receive a kidney transplant or live on dialysis (Zhou et al., 2012). The main causes of ESRD in Egypt, other than diabetic nephropathy, included hypertensive kidney disease, chronic glomerulonephritis, unknown etiology, chronic pyelonephritis, schistosomal obstructive uropathy and schistosomal nephropathy (El-Minshawy, 2011). Abnormal calcium (Ca), phosphorus (P), and vitamin D metabolism are very common in patients with ESRD (Sisman et al., 2012).

Free radicals are reactive species with unpaired electrons (Halliwell and Gutteridge, 2007). Free radicals are formed in both physiological and pathological conditions in mammalian tissues (Mohan and Priya, 2009). Lipid peroxidation is a complex process involving the interaction of oxygen-derived free radicals and polyunsaturated fatty acids, generating very reactive electrophilic aldehydes such as malondialdehyde (MDA) and 4-hydroxynonenal (HNE). These aldehydes modify and damage proteins, causing lysosomal dysfunction and increased lysosomal lipofuscin storage (Schutt et al., 2003; Krohne et al., 2010). Antioxidants are substances that may protect cells from the damage caused by unstable molecules known as free radicals (Hamid et al., 2010). Excess free radicals can result from tissue damage and hypoxia, overexposure to environmental factors (smoking, ultraviolet radiation, and pollutants), a lack of antioxidants, or destruction of free radical scavengers. When the production of damaging free radicals exceeds the capacity of the body's antioxidant defenses to detoxify them, a condition known as oxidative stress occurs (Scheibmeir et al., 2005). Oxidative stress has been defined as a loss of counterbalance between free radicals and/or reactive oxygen species (ROS) production and antioxidant defense mechanisms. There is considerable disequilibrium between oxidants and antioxidants in patients with chronic renal insufficiency/failure (CRI) (Romeu et al., 2010). The occurrence of impaired oxidative status is highlighted by several biomarkers; among them, malondialdehyde (MDA), a terminal compound of lipid peroxidation, is commonly used as an index of oxidative stress (De Vecchi et al., 2009).

Glutathione S-transferase (*GST*) is a multigene family of enzymes that detoxify reactive electrophiles, products of oxidative stress, and known or suspected carcinogenic compounds through conjugation with reduced glutathione (GSH) (Hayes et al., 2005; Sharma et al., 2004; Richard et al., 2000). In humans, *GST* enzymes have been assigned to at least eight separate classes designated alpha, mu, kappa, omega, pi, sigma, theta and zeta, that are encoded by *GSTA*, *GSTM*, *GSTK*, *GSTO*, *GSTP*, *GSTS*, *GSTT* and *GSTZ* genes, respectively. In addition, each class includes several genes and isoenzymes (Hayes and Strange, 2000). Genetic variations of *GST* may influence individual susceptibility to some diseases associated with the deleterious effects of oxidative metabolism (De Alvarenga et al., 2007). *GSTM1* and *GSTT1* polymorphisms are the most common polymorphisms of *GST* enzymes in the human population with major ethnic differences and have been studied most

extensively in many studies (Nowier et al., 2009). The *GSTM1* gene is located on chromosome 1 (1p13.3), while the *GSTT1* gene exists on chromosome 22 (22q11.2). Both of them are polymorphic. The *GSTM1*0* (*GSTM1* deficiency) and *GSTT1*0* (*GSTT1* deficiency) allele represent a deletion of the *GSTM1* and *GSTT1* gene and result in a loss of enzymatic activity (Ye et al., 2004). This study aims to investigate the association between glutathione S-transferase enzyme (*GSTT1* and *GSTM1*) gene polymorphisms and ESRD, to evaluate the oxidative status of ESRD patients and its association with *GSTT1* and *GSTM1* gene polymorphisms, and to study the association between ESRD and lipid peroxidation in the Egyptian population.

2. SUBJECTS AND METHODS

2.1 Subjects

The present study was carried out on end stage renal disease (ESRD) patients (n = 133), with a mean age of 42.97 ± 15.99 years. All the patients were undergoing haemodialysis treatment following diagnosis of ESRD by nephrologists. Some causes of ESRD in the Egyptian patients in this study were: hypertension, vesicoureter reflux, obstructive uropathy, ischaemic heart diseases, drugs and glomerulonephritis, diabetic nephropathy, systemic lupus erythematosus and unknown causes. The control subjects (n = 91), with a mean age of 24.81 ± 13.44 years, they were collected from donor blood bank, and they were free from the diseases. Most of the cases in patients and control group were men, ESRD patients: 95 men / 38 women and the control subjects: 80 men / 11 women. This study was approved by Ethical Board of the Mansoura University. Informed written consent was obtained from all participants, (patients and control subjects), in this study.

Five milliliters (5 ml) of peripheral blood samples were divided into three (3) tubes: 1 ml of blood was collected in an ethylenediaminetetra-acetic acid (EDTA) tube as an anticoagulant for isolation of DNA and the polymerase chain reaction (PCR) technique on these DNA samples was applied, 2 ml of blood were collected in an EDTA tube and centrifuged to obtain plasma for evaluation of the glutathione S-transferase enzyme (*GST*) and 2 ml of blood were collected in a tube without EDTA then centrifuged to obtain serum for estimation of the malondialdehyde (MDA) and biochemical parameters in the ESRD patients and in the control subjects.

2.2 Malondialdehyde (MDA) assay

MDA was determined by the double heating method of Draper and Hadley, (1990). The principle of the method was spectrophotometric measurement of the color produced during the reaction to thiobarbituric acid (TBA) with MDA. For this purpose 2.5 ml trichloroacetic acid (100 g/l) solution was added to 0.5 ml serum in a centrifuge tube and placed in a boiling water bath for 15 min. After cooling in tap water the mixture was centrifuged at 1000 g for 10 min, and 2 ml supernatant was added to 1 ml TBA (6.7 g/l) solution in a test-tube and placed in a boiling water bath for 15 min. The solution was then cooled in tap water and its absorbance was measured using a spectrophotometer at 532 nm.

2.3 Glutathione S-transferase (*GST*) assay

The activity of glutathione S-transferase was measured with 1 mM 1-chloro-2,4-dinitrobenzene and 1 mM glutathione by a method based on the description of Habig et al. (1974). The enzyme and both substrates were incubated in 1 ml of 0.1 M potassium phosphate, pH 6.5, containing 2.5% ethyl alcohol to dissolve 1-chloro-2,4-dinitrobenzene at

30°C. After an addition of 3 ml of 0.33 N HCl to stop the reaction, absorbance at 340 nm was measured.

2.4 Determination of Genotypes

Genomic DNA was isolated and purified from whole blood using a DNA purification kit (Fermentas spin columns, Canada). Analysis for *GSTM1* and *GSTT1* gene polymorphisms was carried out by multiplex PCR using the method described by Abdel-Rahman et al. (1998). Genomic DNA (100-150 ng) was amplified in a total volume of 25 µl reaction mixture containing 20 pmol of each of the following primers: *GSTM1*; forward 5'-GAACTCCCTGAAAAGCTAAAGC-3' and reverse 5' GTTGGGCTCAAATATACGGTGG-3', *GSTT1*, forward: 5'- TTCCTTACTGGTCCTCACATCTC-3' and reverse 5'-TCACGGGATCAT GGCCAGCA-3'. Exon 7 of the CYP1A1 gene was coamplified and used as an internal control, using primers: forward: 5'-GAACTGCCACTTCAGCTGTCT-3' and reverse 5'-CAGCTGCATTTGGAAGTGCTC-3'. Each set of reactions included positive and negative controls. The multiplex PCR method was used to detect the presence or absence of the *GSTT1* and *GSTM1* genes in the genomic DNA samples, simultaneously in the same tube. The reaction mixture was subjected to initial denaturation at 94°C for 2 min, followed by 35 cycles of 94°C for 2 min, 59°C for 1 min and 72°C for 1 min. The final extension was done at 72°C for 10 min. The PCR products were electrophoresed in 2% agarose gels, and visualized by ethidium bromide staining. DNA from samples positive for *GSTM1* and *GSTT1* genotypes yielded bands of 215 bp and 480 bp, respectively, While the internal positive control (CYP1A1) PCR product corresponded to 312 bp, as shown in (Figure 1).




Fig. (1): Ethidium bromide-stained 2% agarose gel of representative multiplex PCR products of *GSTT1* (480 bp) and *GSTM1* (215 bp) genes with CYP1A1 (312 bp) as internal control. DNA Ladder (100 bp): Lane (R). **(A):** *GSTT1* deletion genotype: Lanes (1 and 3). *GSTM1* deletion genotype: Lanes (2, 4 and 6). Both deletion genotypes: Lane (5). **(B):** Both present genotypes: Lanes (1-3). *GSTM1* deletion genotype: Lane (4).

2.5 Statistical Analysis

Data were obtained using SPSS version 15. Results were expressed as means $\pm$ standard deviation (SD). Comparisons between the ESRD patients and control subjects markers were made using chi-square 2x2 analysis and independent t-test. Correlation between two parameters was determined by Pearson's correlation coefficient (r). Chi square and odds ratio were calculated with 95% confidence interval. A *p* value less than 0.05 was considered statistically significant.

3. RESULTS AND DISCUSSION

3.1 Results

Table 1 shows the clinical characteristics of ESRD patients (*n* = 133) and control subjects (*n* = 91). The most important renal functional parameters i.e. serum creatinine, total protein and albumin levels showed significant differences (*P* < 0.0001) between two groups, confirming the absence of any renal disease in the control subjects. The lipid parameters also revealed highly significant differences between ESRD patients and control subjects (*P* < 0.0001).

Table 1. Clinical characteristics of ESRD patients and control subjects

Parameters	ESRD Patients (N = 133) (Mean $\pm$ SD)	Control Subjects (N = 91) (Mean $\pm$ SD)	<i>P</i> -value
Hemoglobin (g/dL)	9.7 $\pm$ 1.87	14.3 $\pm$ 0.95	< 0.0001*
Creatinine (mg/dL)	8.8 $\pm$ 3.54	0.6 $\pm$ 0.18	< 0.0001*
Sodium (mmol/L)	130.7 $\pm$ 5	142.2 $\pm$ 1.9	< 0.0001*
Potassium (mmol/L)	5.2 $\pm$ 0.85	4.4 $\pm$ 0.5	< 0.0001*
Calcium (mg/dL)	9.1 $\pm$ 1.08	10 $\pm$ 0.09	< 0.0001*
Phosphorus (mg/dL)	5.7 $\pm$ 1.78	3.3 $\pm$ 0.67	< 0.0001*
Total Protein (g/dL)	7.28 $\pm$ 0.71	8.3 $\pm$ 0.1	< 0.0001*
Albumin (g/dL)	3.3 $\pm$ 0.37	4.6 $\pm$ 0.2	< 0.0001*
Total Bilirubin (mg/dL)	0.7 $\pm$ 0.25	0.6 $\pm$ 0.2	< 0.0001*
GPT (U/L)	20.2 $\pm$ 12.26	14.3 $\pm$ 2	< 0.0001*
GOT (U/L)	21.3 $\pm$ 10.5	14.4 $\pm$ 5.35	< 0.0001*
Alkaline Phosphatase (U/L)	127.9 $\pm$ 107.8	81.9 $\pm$ 10.75	< 0.0001*
Total Cholesterol (mg/dL)	179.1 $\pm$ 71.14	114.6 $\pm$ 32.3	< 0.0001*
Triglyceride (mg/dL)	224 $\pm$ 104.76	101.4 $\pm$ 62.2	< 0.0001*
HDL (mg/dL)	39.6 $\pm$ 19.9	64.4 $\pm$ 17.38	< 0.0001*
LDL (mg/dL)	112.1 $\pm$ 66.19	72 $\pm$ 33.79	< 0.0001*
Systolic BP (mm Hg)	144.4 $\pm$ 22.1	115.3 $\pm$ 8.3	< 0.0001*
Diastolic BP (mm Hg)	89.5 $\pm$ 12.09	78.7 $\pm$ 3.4	< 0.0001*
Haemodialysis Duration (years)	7.9 $\pm$ 4.05	0	< 0.0001*

*Significant value (*P* < 0.05), Results were expressed as mean $\pm$ SD. SD: standard deviation. Data obtained using independent t-test. ESRD: end stage renal disease.

Table 2 shows the distribution of *GSTT1* and *GSTM1* genotypes and their frequencies in the ESRD patients (*n* = 133) and in the control subjects (*n* = 91). The frequency of *GSTT1* (null or deletion) genotype was 63 (47.4%) in the ESRD patients and 39 (42.9%) in the control

subjects, while the frequency of *GSTT1* (present or positive) genotype was 70 (52.6%) in the ESRD patients and 52 (57.1%) in the control subjects. The frequencies of *GSTT1* (deletion) and *GSTT1* (present) genotypes were not significantly different between ESRD patients and control subjects ($P > 0.05$). The frequency of *GSTM1* (deletion) genotype was significantly increased in the ESRD patients, 85 (63.9%), as compared with the control subjects, 29 (31.9%), ($P < 0.0001$, OR = 3.786, 95% CI = 2.151-6.664), while the frequency of *GSTM1* (present) genotype was significantly lower in the ESRD patients, 48 (36.1%), than in the control subjects, 62 (68.1%).

The frequency of both present genotypes (*GSTT1/GSTM1*) was significantly lower in the ESRD patients, 24 (18%), than in the control subjects, 39 (42.9%). The frequency of *GSTT1* present and *GSTM1* deletion genotypes (*GSTT1/0*) was significantly higher in the ESRD patients, 46 (34.6%), than in the control subjects, 13 (14.3%), ($P = 0.001$, OR = 3.172, 95% CI = 1.595-6.308). The frequency of *GSTT1* deletion and *GSTM1* present genotypes (*0/GSTM1*) in the ESRD patients, 24 (18%), was not significantly different from the control subjects, 23 (25.3%), ($P > 0.05$). The frequency of both deletion genotypes (*0/0*) was significantly higher in the ESRD patients, 39 (29.3%), than in the control subjects, 16 (17.6%), ($P = 0.045$, OR = 1.945, 95% CI = 1.009-3.749).

Table 2. Distribution of *GSTT1* and *GSTM1* genotypes in ESRD and control cases subjects

Marker: <i>GSTT1</i>	ESRD Patients (N = 133) N (%)	Control Subjects (N = 91) N (%)	P-value	OR	95% CI
Null	63 (47.4%)	39 (42.9%)	0.505	1.200	(0.701-2.053)
Present	70 (52.6%)	52 (57.1%)			
Marker: <i>GSTM1</i>	ESRD Patients (N = 133) N (%)	Control Subjects (N = 91) N (%)	P-value	OR	95% CI
Null	85 (63.9%)	29 (31.9%)	< 0.0001*	3.786	(2.151-6.664)
Present	48 (36.1%)	62 (68.1%)			
Genotype Combination	ESRD Patients (N = 133) N (%)	Control Subjects (N = 91) N (%)	P-value	OR	95% CI
<i>GSTT1/GSTM1</i>	24 (18%)	39 (42.9%)	< 0.0001*	0.294	(0.160-0.538)
<i>GSTT1/0</i>	46 (34.6%)	13 (14.3%)	0.001*	3.172	(1.595-6.308)
<i>0/GSTM1</i>	24 (18%)	23 (25.3%)	0.192	0.651	(0.341-1.243)
<i>0/0</i>	39 (29.3%)	16 (17.6%)	0.045*	1.945	(1.009-3.749)

*Significant value ($P < 0.05$). Results obtained using chi-square 2x2 analysis. OR: odds ratio. CI: confidence interval.

Table 3 shows the level of serum malondialdehyde (MDA), the oxidative stress biomarker, was significantly higher in the ESRD patients than in the control subjects ($P < 0.0001$), while the level of plasma glutathione S-transferase enzyme, the antioxidant enzyme, was significantly decreased in the ESRD patients as compared with the control subjects ($P < 0.0001$). The oxidative stress was associated with the ESRD.

Table 3. MDA (oxidative stress biomarker) and GST (antioxidant enzyme) in ESRD patients and control subjects

Parameter	ESRD Patients (N = 133) (Mean $\pm$ SD)	Control Subjects (N = 91) (Mean $\pm$ SD)	P-value
MDA (nmol/mL)	1.99 $\pm$ 1.18	0.97 $\pm$ 0.38	< 0.0001*
GST (mmol/mL)	0.09 $\pm$ 0.03	0.19 $\pm$ 0.07	< 0.0001*

Data were expressed as mean $\pm$ SD. MDA: malondialdehyde. GST: glutathione S-transferase enzyme. *Significant value ($P < 0.05$) obtained using independent t-test.

Table 4 shows the association between MDA and the different GST genotypes, and the association between GST enzyme and the different GST genotypes in the ESRD patients and control cases. The mean value of MDA was significantly higher in all GST genotypes in the ESRD patients than in the control subjects, ($P < 0.05$). While, the mean value of GST enzyme was significantly lower in the GSTT1 (null), GSTT1 (present), GSTM1 (null), GSTM1 (present), GSTT1/GSTM1, GSTT1/0 and 0/GSTM1 genotypes in the ESRD patients than in the control subjects, ($P < 0.05$), and there was nonsignificant decrease in level of GST enzyme in the GST both deletion (0/0) genotypes in both groups (ESRD patients and control subjects), ($P = 0.055$).

Table 4. The Relationship between GST Genotypes and (MDA and GST Enzyme) in ESRD Patients and Control Subjects.

Genotypes	ESRD Patients (N = 133) (Mean $\pm$ SD)	Control Subjects (N = 91) (Mean $\pm$ SD)	P-value
MDA (nmol/ml)			
GSTT1 (Null)	63 (1.97 $\pm$ 1.36)	39 (1.04 $\pm$ 0.44)	< 0.0001*
GSTT1 (Present)	70 (2.01 $\pm$ 0.99)	52 (0.91 $\pm$ 0.31)	< 0.0001*
GSTM1 (Null)	85 (2.10 $\pm$ 1.32)	29 (1.02 $\pm$ 0.36)	< 0.0001*
GSTM1 (Present)	48 (1.78 $\pm$ 0.84)	62 (0.95 $\pm$ 0.38)	< 0.0001*
GSTT1/GSTM1	24(1.70 $\pm$ 0.87)	39 (0.91 $\pm$ 0.31)	< 0.0001*
GSTT1/0	46 (2.16 $\pm$ 1.03)	13 (0.93 $\pm$ 0.31)	< 0.0001*
0/GSTM1	24 (1.87 $\pm$ 0.82)	23 (1.017 $\pm$ 0.47)	< 0.0001*
0/0	39 (2.03 $\pm$ 1.62)	16 (1.08 $\pm$ 0.39)	0.001*
GST (mmol/ml)			
GSTT1 (Null)	63 (0.096 $\pm$ 0.032)	39 (0.17 $\pm$ 0.081)	< 0.0001*
GSTT1 (Present)	70 (0.091 $\pm$ 0.032)	52 (0.21 $\pm$ 0.059)	< 0.0001*
GSTM1 (Null)	85 (0.094 $\pm$ 0.031)	29 (0.14 $\pm$ 0.062)	< 0.0001*
GSTM1 (Present)	48 (0.091 $\pm$ 0.033)	62 (0.22 $\pm$ 0.059)	< 0.0001*
GSTT1/GSTM1	24 (0.085 $\pm$ 0.032)	39 (0.22 $\pm$ 0.049)	< 0.0001*
GSTT1/0	46 (0.094 $\pm$ 0.032)	13 (0.17 $\pm$ 0.069)	0.002*
0/GSTM1	24 (0.097 $\pm$ 0.034)	23 (0.22 $\pm$ 0.073)	< 0.0001*
0/0	39 (0.095 $\pm$ 0.031)	16 (0.115 $\pm$ 0.042)	0.055

*Significant value ($P < 0.05$). Results obtained using independent t-test.

Table 5 shows the Pearson's correlation between MDA and Lipid parameters. There were significant positive correlations between MDA, the oxidative stress biomarker, and total

cholesterol, triglyceride and low density lipoprotein-cholesterol (LDL-cholesterol). There was a significant negative correlation between MDA and high density lipoprotein-cholesterol (HDL-cholesterol) in the studied subjects (ESRD patients and control subjects), as shown in (Figure 2).


253
254
255

Table 5. Correlation between MDA and Lipid parameters among the studied subjects

MDA (nmol/mL)		
Parameter	r-value	P-value
TC (mg/dL)	0.212	0.001*
TG (mg/dL)	0.268	< 0.0001*
HDL (mg/dL)	-0.152	0.022*
LDL (mg/dL)	0.333	< 0.0001*

*Significant value ($P < 0.05$). Results obtained by Pearson's correlation coefficient.

256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279



280
281
282
283
284
285

Fig. (2): Correlation between malondialdehyde (MDA) and lipid parameters among the studied subjects. **(A):** MDA, significant positive correlation, with total cholesterol (TC) ($r = 0.212$, $P = 0.001$). **(B):** MDA, significant positive correlation, with triglyceride (TG) ($r = 0.268$, $P = 0.022$). **(C):** MDA, significant negative correlation, with HDL-Cholesterol ($r = -0.152$, $P < 0.0001$). **(D):** MDA, significant positive correlation, with LDL-Cholesterol ($r = 0.333$, $P < 0.0001$). Significant value ($P < 0.05$).

*Corresponding author: Email: Ba_Janna2002@yahoo.com.

3.2 Discussion

End stage renal disease (ESRD) is a multifactorial disease. Clinically, ESRD is an advanced form of chronic renal failure (CRF) where renal function has declined to ~10% of the normal prior to initiation of dialysis or transplantation (Tripathi et al., 2008). Glutathione S-transferases (GSTs) belong to a group of multigene and multifunctional detoxification enzymes, which defend cells against a wide variety of toxic insults from chemical, metabolites, and oxidative stress (Nowier et al., 2009). In this present study, we have observed that there were highly significant differences in the biochemical parameters between ESRD patients and control subjects.

Our study showed that the frequency of *GSTM1* (present) and *GSTT1/GSTM1* genotypes were significantly lower in the ESRD patients than in the control subjects, whereas the *GSTM1* (null), *GSTT1/0* and *0/0* genotypes were significantly higher in the ESRD patients as compared with the healthy subjects in the Egyptian population. These results were consistent with other studies, a study from India done by Agrawal et al. (2007) who reported that the (null) genotype of *GSTM1* and *GSTT1* were associated with the higher risk for CRF. Also, a study in China, Yang et al. (2004) noted that the *GSTT1* (null) genotype subjects may be at risk for CRF development among patients with diabetes, whereas there is no such risk for subject with hypertension. In contrast, a study done by Akgul et al. (2012) who suggested that the *GSTM1* and *GSTT1* null genotypes were not a risk factor for CRF development.

This present study showed a significant increase in serum MDA level in the Egyptian ESRD patients as compared with the control subjects. Our results were in agreement with several studies demonstrated that MDA is a good indicator for evaluating oxidative stress in degenerative disease like chronic kidney disease (CKD), and MDA level was significantly increased in the CKD patients as compared with the control subjects done by Suresh et al. (2008), Padalkar et al. (2012) and Patel et al. (2012). Also, a study done by Suvakov et al. (2013) who showed that the increased oxidative stress is a hallmark of ESRD.

This present study showed that the *GST* enzyme levels, the antioxidant enzyme, were significantly decreased in the ESRD patients as compared with the control subjects. These results confirmed those of Pagliuso et al. (2008) who found that decreased the *GST* levels in CRF.

The findings of this present study investigated that the mean value of MDA was significantly higher in the *GSTT1* (null), *GSTT1* (present), *GSTM1* (null), *GSTM1* (present), *GSTT1/GSTM1*, *GSTT1/0*, *0/GSTM1* and both deletion (*0/0*) genotypes in the ESRD patients than in the control subjects, whereas the mean value of *GST* enzyme was significantly lower in the *GSTT1* (null), *GSTT1* (present), *GSTM1* (null), *GSTM1* (present), *GSTT1/GSTM1*, *GSTT1/0* and *0/GSTM1* genotypes, while the level of *GST* enzyme in the both deletion (*0/0*) was not significantly lower in the ESRD patients than the control subjects. These results were in agreement with Datta et al. (2010) who reported that the *GST* levels were lower among subjects with deletion in one/both *GST* genes, whereas MDA levels were found to be correspondingly raised, in both diabetic and nondiabetic CKD.

MDA is a byproduct of lipid peroxidation. Increased lipid peroxidation has been observed in dialysis patients and in predialysis adults with advanced CRF (Zwolinska et al., 2004; Suresh et al., 2008). In this study, by using Pearson's correlation, there were significant positive correlations between MDA and total cholesterol, triglyceride, and LDL-cholesterol. There was a significant negative correlation between MDA and HDL-cholesterol among the studied subjects. These results were in agreement with other results done by Patel et al. (2012).

This present study demonstrated that there were lipid abnormalities and oxidative stress in the ESRD patients and these results were in agreement with Abrass (2004), Padalkar et al. (2012) and Patel et al. (2012).

4. CONCLUSION

The findings of this study demonstrates that: the *GSTM1* (null), *GSTT1/0* and both deletion (0/0) genotypes are significantly increased in the ESRD patients as compared with the control subjects, whereas the *GSTM1* (present) and *GSTT1/GSTM1* genotypes are significantly decreased in the ESRD patients as compared with the control subjects. There were highly significant genetic linkage between *GSTT1* and *GSTM1* genes, and end stage renal disease (ESRD). The *GSTM1* (null), *GSTT1/0* and both deletion (0/0) genotypes are considered as risk factors for ESRD and can be used as predicting and prognostic factors for ESRD, while the *GSTM1* (present) and *GSTT1/GSTM1* genotypes are considered as protective factors against the ESRD in the Egyptian population.

Also, this study evaluates the oxidative status of the studied groups (ESRD patients and control subjects) through measurement of serum level of malondialdehyde (MDA), the biomarker of oxidative stress and lipid peroxidation, and plasma level of glutathione S-transferase enzyme (*GST*), the antioxidant enzyme, for both groups, then the results are compared and show that there are a significant increase in the level of MDA and a significant decrease in the level of *GST* enzyme in the ESRD patients as compared with the healthy group. According to these results, the oxidative stress is strongly associated with ESRD.

This present study investigates that the level of MDA is significantly increased in all *GST* genotypes in the ESRD patients as compared with the control group. So, there are significant association between the genetic risk factors of *GSTT1* and *GSTM1* genes in the ESRD, (*GSTM1* null, *GSTT1/0* and 0/0 genotypes), and high level of MDA in the ESRD patients, while the level of *GST* enzyme is significantly decreased in *GST* genotypes except the both deletion (0/0) genotypes, in which the level of *GST* enzyme is not significantly decreased in the ESRD patients as compared with the control subjects. There are significant association between the genetic risk factors of *GSTT1* and *GSTM1* genes in the ESRD, (*GSTM1* null and *GSTT1/0* genotypes), and low level of *GST* enzyme in the ESRD patients. This association between the oxidative stress and genetic risk factors of *GSTT1* and *GSTM1* genes in the ESRD increases the risk of these genetic factors in the ESRD patients.

In the studied subjects (ESRD patients and control subjects), there are significant positive correlations between serum MDA, the lipid peroxidation biomarker, and total cholesterol (TC), triglyceride (TG) and low density lipoprotein-cholesterol (LDL-cholesterol). There is a significant negative correlation between MDA and high density lipoprotein-cholesterol (HDL-cholesterol). This reflects that the lipid peroxidation is one of the most important complications of ESRD in the Egyptian population.

REFERENCES

1. Abdel-Rahman SZ, Anwar WA, Abdel-Aal WE, Mostafa HM, Au WW. *GSTM1* and *GSTT1* genes are potential risk modifiers of bladder cancer. *Cancer Detection Prev.* 1998; 22:129-38.
2. Abrass CK. Cellular Lipid Metabolism and the Role of Lipids in Progressive Renal Disease. *Am J Nephrol.* 2004;24:46-53.
3. Agrawal S, Tripathi G, Khan F, Sharma R, Baburaj VP. Relationship between GSTs gene polymorphism and susceptibility to end stage renal disease among north Indians. *Renal Failure.* 2007;29(8):947-953.

392 4. Akgul SU, Oguz FS, Çaliskan Y, Kekik C, Gürkan H, Türkmen A, Nane I, Aydın F. The
393 effect of glutathion s-transferase polymorphisms and anti-GSST1 antibodies on allograft
394 functions in recipients of renal transplant. *Transplantation Proceedings*. 2012;44:1679-1684.
395 5. Datta SK Kumar V, Pathak R, Tripathi AK, Ahmed RS, Kalra OP, Banerjee BD.
396 Association of glutathione S-transferase M1 and T1 gene polymorphism with oxidative stress
397 in diabetic and nondiabetic chronic kidney disease. *Renal Failure*. 2010;32(10):1189-95.
398 6. De Alvarenga MP, Pavarino-Bertelli EC, Abbud-Filho M. Combination of angiotensin-
399 converting enzyme and methylenetetrahydrofolate reductase gene polymorphisms as
400 determinant risk factors for chronic allograft dysfunction. *Transplant Proc* 2007;39:78.
401 7. De Vecchi AF, Bamonti F, Novembrino C, Ippolito S, Guerra L, Lonati S, Salini S, Aman
402 CS, Scurati-Manzoni E, Cighetti G. Free and total plasma malondialdehyde in chronic renal
403 insufficiency and in dialysis patients. *Nephrol Dial Transplant*. 2009;24:2524-2529.
404 8. Drapper HH, Hadley M. Malondialdehyde determination as index of lipid peroxidation.
405 *Methods in Enzymology*. 1990;186:421-431.
406 9. El-Minshawy O. End stage renal disease in El-Minia governorate, Egypt: data of year.
407 *Nephrol-Urol Mon*. 2011;3 (2):118-121.
408 10. Habig WH, Pabst MJ, Jacoby WB. Glutathione s-transeferase: The first enzymatic step
409 in mercapturic acid formation. *J Biol Chem*. 1974;249:7130-7139.
410 11. Halliwell B, Gutteridge JMC. Free radicals in biology and medicine. 4th ed. Oxford
411 University Press, UK; 2007.
412 12. Hamid AA, Aiyelaagbe OO, Usman LA, Ameen OM, Lawal A. Antioxidants: its medicinal
413 and pharmacological applications. *African Journal of Pure and Applied Chemistry*.
414 2010;4(8):142-151.
415 13. Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. *Annu Rev Pharmacol*
416 *Toxicol*. 2005;45:51-88.
417 14. Hayes JD, Strange RC. Glutathione S-transferase polymorphisms and their biological
418 consequences. *Pharmacology*. 2000;61:154-66.
419 15. Krohne TU, Stratmann NK, Kopitz J, Holz FG. Effects of lipid peroxidation products on
420 lipofuscinogenesis and autophagy in human retinal pigment epithelial cells. *Exp Eye Res*.
421 2010;90:465-471.
422 16. Malekmakan L, Haghpanah S, Pakfetrat M, Malekmakan A, Parviz K. Causes of chronic
423 renal failure among Iranian hemodialysis patients. *Saudi J Kidney Dis Transpl*.
424 2009;20(3):501-504.
425 17. Mohan SK, Priya VV. Lipid peroxidation, glutathione, ascorbic acid, vitamin E,
426 antioxidant enzyme and serum homocysteine status in patients with polycystic ovary
427 syndrome. *Biology and Medicine*. 2009;1(3):44-49.
428 18. Nowier SR, Kashmiry NK, Abdel Rasool HA, Morad H, Ismail S. Association of type 2
429 diabetes mellitus and glutathione s transferase (GSTM1 and GSTT1) genetic polymorphism.
430 *Journal of Medicine and Medical Sciences*. 2009;4(2):181-188.
431 19. Padalkar RK, Shinde AV, Patil SM. Lipid profile, serum malondialdehyde, superoxide
432 dismutase in chronic kidney diseases and Type 2 diabetes mellitus. *Biomedical Research*.
433 2012;23(2):207-210.
434 20. Pagliuso RG, Abbud-Filho M, Alvarenga MPS, Ferreira-Baptista MAS, Biselli JM, Goloni-
435 Bertollo EM, Pavarino-Bertelli EC. Role of glutathione s-transferase polymorphisms and
436 chronic allograft dysfunction. *Transplantation Proceedings*. 2008;40:743-745.
437 21. Patel ML, Rekha S, Srivastava AN. Dyslipidemia and oxidative stress in maintenance
438 hemodialysis patient-an emerging threat to patient. *International Journal of Scientific and*
439 *Research Publications*. 2012;2250-3153.
440 22. Richard CS, Peter WJ, Anthony AF. Glutathione S-transferase: genetics and role in
441 toxicology. *Toxicol Lett*. 2000;112-113:357-63.
442 23. Romeu M, Nagues R, Marcas L, Sánchez-Martos V, Mulero M. Evaluation of oxidative
443 stress biomarkers in patients with chronic renal failure: a case control study. *BMC Research*
444 *Notes*. 2010;3:20.

- 445 24. Scheibmeir HD, Christensen K, Whitaker SH, Jegaethesan J, Clancy R, Pierce JD. A
446 review of free radicals and antioxidants for critical care nurses. *Intensive and Critical Care*
447 *Nursing*. 2005;21:24-28.
- 448 25. Schutt F, Bergmann M, Holz FG, Kopitz J. Proteins modified by malondialdehyde, 4-
449 hydroxynonenal, or advanced glycation end products in lipofuscin of human retinal pigment
450 epithelium. *Invest Ophthalmol Vis Sci*. 2003;44:3663-3668.
- 451 26. Sharma R, Yang Y, Sharma A, Awasthi S, Awasthi YC. Antioxidant role of glutathione S
452 transferases: protection against oxidant toxicity and regulation of stress-mediated apoptosis.
453 *Antioxid Redox Signal*. 2004;6:289-300.
- 454 27. Sisman Y, Gokce C, Sipahioglu M, Ertas ET, Unal A, Oymak O, Utas C. Torus palatinus
455 in end-stage renal disease patients receiving peritoneal dialysis: does renal osteodystrophy
456 play a role. *Journal of Dental Sciences*. 2012;7:154-158.
- 457 28. Suresh DR, Silvia CRWD, Agarwal R. Lipid peroxidation and total antioxidant capacity in
458 patients with chronic renal failure. *Asian Journal of Biochemistry*. 2008;3(5):315-319.
- 459 29. Suvakov S, Damjanovic T, Stefanovic A, Pekmezovic T, Savic-Radojevic A, Pljesa-
460 Ercegovac M, Matic M, Djukic T, Coric V, Jakovljevic J, Ivanisevic J, Pljesa S, Jelic-Ivanovic
461 Z, Mimic-Oka J, Dimkovic N, Simic T. Glutathione S-transferase A1, M1, P1 and T1 null or
462 low-activity genotypes are associated with enhanced oxidative damage among
463 haemodialysis patients. *Nephrol. Dial. Transplant*. 2013;28(1):202-212.
- 464 30. Tripathi G, Sharma RK, Baburaj VP, Sankhwar SN, Jafar T, Agrawal S. Genetic risk
465 factors for renal failure among North Indian ESRD patients. *Clinical Biochemistry*.
466 2008;41:525-531.
- 467 31. Zhou T, Yin S, Qin Y. Association between angiotensin-converting enzyme
468 insertion/deletion gene polymorphism and end-stage renal disease susceptibility. *Journal of*
469 *the Renin-Angiotensin-Aldosterone System*. 2012;1-10
- 470 32. Zwolinska D, Grzeszczak W, Kilis-Pstrusinska K, Szprynger K, Szczepanska N. Lipid
471 peroxidation and antioxidant enzymes in children with chronic renal failure. *Pediatr Nephrol*.
472 2004;19(8):888-892.
- 473 33. Yang Y, Kao MT, Chang CC, et al. Glutathione S-transferase T1 deletion is a risk factor
474 for developing end-stage renal disease in diabetic patients. *Int J Mol Med*. 2004;14:855.
- 475 34. Ye Z, Song H, Guo Y. Glutathione S-transferase M1, T1 status and the risk of head and
476 neck cancer: a meta-analysis. *J Med Genet*. 2004;41:360-365.